7 Red Flags When Evaluating Exosome Suppliers
Not every supplier is what they claim. Here's what to watch for.
The exosome supply market has grown rapidly, and with growth comes variability in quality. We've analyzed 10+ US exosome suppliers and found consistent patterns that separate premium suppliers from those cutting corners.
- Red flag #1: "Our COA is available after purchase." Every legitimate supplier can provide batch-specific documentation before taking payment. If they won't, ask why.
- Red flag #2: In-house COA with no third-party verification. The same organization that produced the material also tested it — and has a financial interest in passing it. Independent testing removes this conflict.
- Red flag #3: Vague or undisclosed tissue source. "MSC-derived" isn't enough. Wharton's Jelly, amniotic fluid, and cord blood all produce different exosome profiles. The source should be disclosed without hesitation.
- Red flag #4: No batch-level traceability. If a supplier can't trace your order to a specific donor and production run, you have no liability protection and no way to identify the source of any issue.
- Red flag #5: No numerical endotoxin result. "Compliant" or "Pass" without a specific EU/mL value means they may not have tested — or the result wasn't publishable.
- Red flag #6: Pricing requires enrollment first. Requiring NPI verification or account creation before showing pricing creates friction that masks comparison shopping.
- Red flag #7: Exaggerated therapeutic claims. No exosome product is FDA-approved for therapeutic use. A supplier that claims otherwise is a regulatory liability waiting to happen.
The fix is simple: Ask for the current-batch, independent COA before you pay. If they can't produce one, move on.
See how suppliers compare →